Early clinical experience of radiotherapy of prostate cancer with volumetric modulated arc therapy
Authors:
- Gianfranco A PesceGPGianfranco A Pesce
- Alessandro ClivioACAlessandro Clivio
- Luca CozziLCLuca Cozzi
- Giorgia NicoliniGNGiorgia Nicolini
- Antonella RichettiARAntonella Richetti
- Emanuela SalatiESEmanuela Salati
- Mariacarla ValliMVMariacarla Valli
- Eugenio VanettiEVEugenio Vanetti
- Antonella FogliataAFAntonella Fogliata
Open Access
- 16 June 2010
- journal article
- clinical trial
- Published by Springer Nature in Radiation Oncology
- Vol. 5 (1) , 54
Abstract
Background: To report about initial clinical experience in radiation treatment of carcinoma of prostate with volumetric modulated arcs with the RapidArc (RA) technology. Methods: Forty-five patients with a median age of 72 ± 3, affected by prostate carcinoma (T1c: 22 patients, T2a-b: 17 patients, T3a-b: 6 patients. N0: 43 patients, N1-Nx: 2 patients, all M0), with initial PSA of 10.0 ± 3.0 ng/mL, were treated with RapidArc in a feasibility study. All patients were treated with single arc using 6MV photons. Dose prescription ranged between 76 (7 patients) and 78 Gy (38 patients) in 2Gy/fraction. Plan quality was assessed by means of Dose Volume Histogram (DVH) analysis. Technical parameters of arcs and pre-treatment quality assurance results (Gamma Agreement Index, GAI) are reported to describe delivery features. Early toxicity was scored (according to the Common Terminology Criteria of Adverse Effects scale, CTCAE, scale) at the end of treatment together with biochemical outcome (PSA). Results: From DVH data, target coverage was fulfilling planning objectives: V95% was in average higher than 98% and V107%~0.0% (D2%~104.0% in average). Homogeneity D5%-D95% ranged between 6.2 ± 1.0% to 6.7 ± 1.3%. For rectum, all planning objectives were largely met (e.g. V70Gy = 10.7 ± 5.5% against an objective of < 25%) similarly for bladder (e.g. D2% = 79.4 ± 1.2Gy against an objective of 80.0Gy). Maximum dose to femurs was D2% = 36.7 ± 5.4Gy against an objective of 47Gy. Monitor Units resulted: MU/Gy = 239 ± 37. Average beam on time was 1.24 ± 0.0 minutes. Pre-treatment GAI resulted in 98.1 ± 1.1%. Clinical data were recorded as PSA at 6 weeks after RT, with median values of 0.4 ± 0.4 ng/mL. Concerning acute toxicity, no patient showed grade 2-3 rectal toxicity; 5/42 (12%) patients experienced grade 2 dysuria; 18/41 (44%) patients preserved complete or partial erectile function. Conclusion: RapidArc proved to be a safe, qualitative and advantageous treatment modality for prostate cancer.Keywords
This publication has 25 references indexed in Scilit:
- Volumetric Modulated Arc Therapy: Planning and Evaluation for Prostate Cancer CasesInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2010
- A treatment planning study comparing volumetric arc modulation with RapidArc and fixed field IMRT for cervix uteri radiotherapyRadiotherapy and Oncology, 2008
- Volumetric Modulated Arc Therapy for Delivery of Prostate Radiotherapy: Comparison With Intensity-Modulated Radiotherapy and Three-Dimensional Conformal RadiotherapyInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2008
- The GLAaS algorithm for portal dosimetry and quality assurance of RapidArc, an intensity modulated rotational therapyRadiation Oncology, 2008
- Observations on Real-Time Prostate Gland Motion Using Electromagnetic TrackingInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2008
- Does Intensity Modulated Radiation Therapy (IMRT) prevent additional toxicity of treating the pelvic lymph nodes compared to treatment of the prostate only?Radiation Oncology, 2008
- Volumetric modulated arc therapy: IMRT in a single gantry arcMedical Physics, 2007
- Multi-institutional clinical experience with the Calypso System in localization and continuous, real-time monitoring of the prostate gland during external radiotherapyInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2007
- GLAaS: An absolute dose calibration algorithm for an amorphous silicon portal imager. Applications to IMRT verificationsMedical Physics, 2006
- Treatment of prostate cancer with radiotherapy: should the entire seminal vesicles be included in the clinical target volume?International Journal of Radiation Oncology - Biology - Physics (IJROBP), 2002